Currently, PSMA is the only cell surface protein associated with clinical benefit when therapeutically targeted with an FDA-approved drug [PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)] for advanced prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.